The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
Open accessAbstract
BACKGROUND Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. We assessed the addition of pembrolizumab to concurrent chemoradiotherapy for locally advanced HNSCC. METHODS In the randomised, double-blind, phase 3 KEYNOTE-412 trial, participants with newly diagnosed, high-risk, unresected locally advanced HNSCC from 130 medical centres globally were randomly assigned (1:1) to pembrolizumab (200 mg) plus chemoradiotherapy or placebo plus chemoradiotherapy. Randomisation was done using an interactive response technology system and was stratified by investigator's choice of radiotherapy regimen, tumour site and p16 status, and disease stage, with participants randomly assigned in blocks of four per stratum. Participants, investigators, and sponsor personnel were masked to treatment assignments. Local pharmacists were aware of assignments to support treatment preparation. Pembrolizumab and placebo were administered intravenously once every 3 weeks for up to 17 doses (one before chemoradiotherapy, two during chemoradiotherapy, 14 as maintenance therapy). Chemoradiotherapy included cisplatin (100 mg/m2) administered intravenously once every 3 weeks for two or three doses and accelerated or standard fractionation radiotherapy (70 Gy delivered in 35 fractions). The primary endpoint was event-free survival analysed in all randomly assigned participants. Safety was analysed in all participants who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT03040999, and is active but not recruiting. FINDINGS Between April 19, 2017, and May 2, 2019, 804 participants were randomly assigned to the pembrolizumab group (n=402) or the placebo group (n=402). 660 (82%) of 804 participants were male, 144 (18%) were female, and 622 (77%) were White. Median study follow-up was 47·7 months (IQR 42·1-52·3). Median event-free survival was not reached (95% CI 44·7 months-not reached) in the pembrolizumab group and 46·6 months (27·5-not reached) in the placebo group (hazard ratio 0·83 [95% CI 0·68-1·03]; log-rank p=0·043 [significance threshold, p≤0·024]). 367 (92%) of 398 participants treated in the pembrolizumab group and 352 (88%) of 398 participants treated in the placebo group had grade 3 or worse adverse events. The most common grade 3 or worse adverse events were decreased neutrophil count (108 [27%] of 398 participants in the pembrolizumab group vs 100 [25%] of 398 participants in the placebo group), stomatitis (80 [20%] vs 69 [17%]), anaemia (80 [20%] vs 61 [15%]), dysphagia (76 [19%] vs 62 [16%]), and decreased lymphocyte count (76 [19%] vs 81 [20%]). Serious adverse events occurred in 245 (62%) participants in the pembrolizumab group versus 197 (49%) participants in the placebo group, most commonly pneumonia (43 [11%] vs 25 [6%]), acute kidney injury (33 [8%] vs 30 [8%]), and febrile neutropenia (24 [6%] vs seven [2%]). Treatment-related adverse events led to death in four (1%) participants in the pembrolizumab group (one participant each from aspiration pneumonia, end-stage renal disease, pneumonia, and sclerosing cholangitis) and six (2%) participants in the placebo group (three participants from pharyngeal haemorrhage and one participant each from mouth haemorrhage, post-procedural haemorrhage, and sepsis). INTERPRETATION Pembrolizumab plus chemoradiotherapy did not significantly improve event-free survival compared with chemoradiotherapy alone in a molecularly unselected, locally advanced HNSCC population. No new safety signals were seen. Locally advanced HNSCC remains a challenging disease that requires better treatment approaches. FUNDING Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Self-citationBurtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32591-7 · Cited by 3,336
Self-citationOverall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Lee, N. Y., Ferris, R. L., Psyrri, A., Haddad, R. I., Tahara, M., Bourhis, J., Harrington, K., Chang, P. M.-H., Lin, J.-C., Razaq, M. A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30737-3 · Cited by 661
Self-citationRahim, M. K., Okholm, T. L. H., Jones, K. B., McCarthy, E. E., Liu, C. C., Yee, J. L., Tamaki, S. J., Marquez, D. M., Tenvooren, I., Wai, K., et al. (2023) · Cell · doi:10.1016/j.cell.2023.02.021 · Cited by 455
Powell, S. F., Gold, K. A., Gitau, M. M., Sumey, C. J., Lohr, M. M., McGraw, S. C., Nowak, R. K., Jensen, A. W., Blanchard, M. J., Fischer, C. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03156 · Cited by 116
Cited by
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
Uppaluri, R., Haddad, R. I., Tao, Y., Le Tourneau, C., Lee, N. Y., Westra, W., Chernock, R., Tahara, M., Harrington, K. J., Klochikhin, A. L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415434 · Cited by 410
Self-citationSakai, S. A., Oyoshi, H., Nakamura, M., Taki, T., Nomura, K., Hojo, H., Hirata, H., Motegi, A., Nakamura, Y., Zenkoh, J., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03088-0 · Cited by 15
Metadata
- Authors
- Machiels, J.-P., Tao, Y., Licitra, L., Burtness, B., Tahara, M., Rischin, D., Alves, G., Lima, I. P. F., Hughes, B. G. M., Pointreau, Y., Aksoy, S., Laban, S., Greil, R., Burian, M., Hetnał, M., Delord, J.-P., Mesía, R., Taberna, M., Waldron, J. N., Simon, C., Grégoire, V., Harrington, K. J., Swaby, R. F., Zhang, Y., Gumuscu, B., Bidadi, B., Siu, L. L., Rischin, D., Hughes, B. G., Gao, B., McGrath, M., Greil, R., Thurnher, D., Fuereder, T., Burian, M., Rottey, S., Machiels, J.-P., Clement, P. M., Henry, S., Deheneffe, S., Vasconcelos Alves, G., Lima, I. P. F., Mourão Dias, J., De Marchi, P. R. M., Mak, M. P., Pereira de Santana Gomes, A. J., Oliveira de Castro Junior, D., Motta, T. C., Agostinho Padoan, M. L., Victorina, A. P., de Azevedo, S. J., Siu, L. L., Brule, S., Hilton, J., Wang, C. S., Bouganim, N., Webster, M., Walker, J., Chua, N., Zambrano, A. R., Quiroga Echeverri, A., Niño Gomez, O. M., Ortiz, C. A., Rojas, L., Cardona Zorilla, A., Urrego Meléndez, O. M., Holečková, P. B., Melichar, B., Cvek, J., Prausová, J., Vošmik, M., Delord, J.-P., Zasadny, X., Geoffrois, L., Tao, Y., Pointreau, Y., Fietkau, R., Haderlein, M., Mueller, A. H., Schroeder, U., Wollenberg, B., Laban, S., Ivanyi, P., Gruenwald, V., Schafhausen, P., Gutfeld, O., Gluck, I., Popovtzer, A., Meirovitz, A., Billan, S., Brenner, B., Popovtzer, A., Limon, D., Licitra, L., Perri, F., Caponigro, F., Violati, M., Ferrari, D., Nole, F., Bertolini, F., Livi, L., Ghi, M. G., Imarisio, I., Tahara, M., Homma, A., Ueda, T., Asada, Y., Yamazaki, T., Matsumoto, K., Fujii, T., Ikeda, S., Takahashi, S., Kinoshita, T., Sasaki, K., Tsuji, A., Ahn, M.-J., Cho, B. C., Lee, K.-W., Lee, K. H., Choi, M. K., Yun, H. J., Hendriks, M. P., Oosting, S. F., Buter, J., Van Meerten, E., Graham, J., Kawecki, A., Debicka, I., Maciejczyk, A., Pysz, M., Filarska, D., Hetnał, M., Koralewski, P., Wygoda, A., Składowski, K., Talerczyk, M., Berrocal Jaime, A., Pérez Segura, P., Braña García, I., Basté Rotllan, N., Mesía Nin, R., Taberna Sanz, M., Iglesias Docampo, L., Soria Rivas, A., Rueda Domínguez, A., Trigo Pérez, J. M., Hong, R.-L., Li, S.-H., Wang, H.-M., Yen, C.-J., Yang, M.-H., Chang, Y.-F., Liu, Y.-C., Lin, J.-C., Ekenel, M., Harputluoğlu, H., Aksoy, S., Özyilkan, Ö., Bılıcı, A., Şendur, M. A. N., Arslan, C., Harrington, K., Ramkumar, S., Gujral, D., Stewart, S., Powell, M., Sibtain, A., Roques, T., Yip, K., Mirza, A., Sivaramalingam, M., Belman, N. D., Agarwala, S., Anderson, I., Patel, A., Maggiore, R., Baumgart, M., Burtness, B., Fidler, M. J., Kaur, V., Gaughan, E., Worden, F., Rodriguez, C. P., Sukari, A., Wong, D., Yom, S., Walsh, W. V., Fiorillo, J. A., Yorio, J. T., & Obara, G. S.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2024-05
- Volume
- 25
- Issue
- 5
- Pages
- 572-587
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4393301802
- Cited by
- 248
- References
- 6
- FWCI
- 95.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(24)00100-1
- The paper
- Machiels, J.-P., Tao, Y., Licitra, L., Burtness, B., Tahara, M., Rischin, D., Alves, G., Lima, I. P. F., Hughes, B. G. M., Pointreau, Y., Aksoy, S., Laban, S., Greil, R., Burian, M., Hetnał, M., Delord, J.-P., Mesía, R., Taberna, M., Waldron, J. N., . . . Obara, G. S. (2024). Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(24)00100-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.